Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvedBy |
gptkb:FDA
2022 |
| gptkbp:ATCCode |
L01EX25
|
| gptkbp:brand |
Lytgobi
|
| gptkbp:CASNumber |
1448169-86-9
|
| gptkbp:chemicalFormula |
C26H20FN5O3
|
| gptkbp:developer |
gptkb:Taiho_Pharmaceutical
|
| gptkbp:hasSMILES |
C1=CC=C(C=C1)C2=NC(=C(N=C2C3=CC=CC=C3)NC(=O)C4=CC=CC=C4F)C(=O)N5CCOCC5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Futibatinib
|
| gptkbp:indication |
unresectable intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
469.47 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue hyperphosphatemia nail toxicity stomatitis |
| gptkbp:synonym |
gptkb:TAS-120
|
| gptkbp:target |
gptkb:FGFR2
|
| gptkbp:UNII |
6Q1K1Q1K0I
|
| gptkbp:usedFor |
cholangiocarcinoma
|
| gptkbp:bfsParent |
gptkb:CD332
|
| gptkbp:bfsLayer |
7
|